Abstract Migrastatin (MGS) is a Streptomyces metabolite that inhibits cancer cell migration. In this study, we found that MGS also enhanced the cytotoxicity of vinblastine, vincristine, and taxol in P-glycoprotein-overexpressing VJ-300 cells and P388/VCR cells. Furthermore, MGS increased the intracellular concentration of labeled vinblastine, vincristine, and taxol in both VJ-300 cells and P388/VCR cells. P-glycoprotein was photolabeled with [ 3 H]azidopine, but this photolabeling was significantly inhibited in the presence of MGS. These results indicated that MGS directly interacts with and inhibits P-glycoprotein, thereby sensitizing drug-resistant cells to anticancer drugs.
Introduction
The development of drug resistance in the treatment of cancer continues to challenge oncologists. The hallmark of multidrug resistance is cross-resistance to multiple structurally unrelated compounds, such as the anthracyclines, taxanes, vinca alkaloids, and epipodophilotoxins [1, 2] . The MDR-1 gene mediates one of the most extensively studied mechanisms of drug resistance [3] . The protein product of the MDR-1 gene, P-glycoprotein (Pgp), is a 170-kDa ATPdependent efflux pump located in the plasma membrane [4, 5] . Expression of this pump decreases intracellular drug concentration rendering tumor cells drug resistant. Because P-glycoprotein would be an important molecular target for cancer therapy, we searched for a compound that modulates its function in a library of natural products. In this paper, we report that migrastatin (MGS), which was originally isolated from Streptomyces sp. MK929-43F1 as an inhibitor of cancer cell migration [6ϳ9], enhances the cytotoxicity of anticancer drugs in P-glycoprotein-overexpressing cells.
Materials and Methods

Materials
Migrastatin (MGS) was isolated from Streptomyces sp. as described previously [6] . Vinblastine, vincristine, and taxol were obtained from Wako Pure Chemical Industries, Ltd. (Tokyo, Japan 
Cell Culture
Human epidermoid carcinoma KB/S cells, vincristineresistant VJ-300 cells [10] , mouse leukemia P388/S cells and vincristine-resistant P388/VCR cells [11] were kindly provided by Dr. M. Hayashi (Kitasato Institute). VJ-300 cells and P388/VCR cells were cultured in medium containing 10 ng/ml vincristine to maintain their drug resistance.
MTT Cell Growth Assay
The cells were seeded at 5ϫ10 3 cells in 200 ml of growth medium in 96-well plates. Drugs were added, and the cells were further incubated for 3 days. Ten microliters of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in phosphate-buffered saline (PBS) was added to each well, and the plate was incubated at 37°C for 4 hours. Then, 100 m l of DMSO was added to cells. The amount of Formazan formed was measured at 570 nm using a MRP-A4 micro plate reader (Tosho).
Measurement of Intracellular Concentration of Anticancer Drugs in Cancer Cells
The cells were seeded at 5ϫ10 4 Preparation and Photoaffinity Labeling of Plasma Membrane VJ-300 cells were homogenized in buffer A (10 mM TrisHCl buffer, pH 7.5, 25 mM sucrose, 0.2 mM CaCl 2 and 1 mM phenylmetylsulfonyl fluoride (PMSF)). The cell homogenate was diluted 4 fold with buffer B (10 mM TrisHCl, pH 7.5, and 25 mM sucrose) and then centrifuged at 1000ϫg for 10 minutes. The supernatant was layered onto a 35% sucrose solution (10 mM Tris-HCl, pH 7.5, 35% sucrose, and 1 mM EDTA) and centrifuged at 10,000ϫg for 30 minutes. The membrane fraction at the interface was collected, resuspended in buffer B, and then centrifuged at 100,000ϫg for 60 minutes. The pellets (plasma membrane) were resuspended in buffer C (10 mM Tris-HCl, pH 7.5, 250 mM sucrose, and 1 mM PMSF) and incubated with 8.3 nM [ 3 H]azidopine and drugs for 1 hour at 4°C. The mixture was irradiated for 15 minutes at 4°C with an UV lamp (312 nm), and photolabeled membranes were analyzed by SDS-PAGE. The gel was fixed in a mixture of 30% acetic acid and 10% methanol, treated with Autoradiography Enhancer (PerkinElmer, Boston, MA) for 1 hour, dried, and then exposed for 2 weeks at Ϫ80°C using Kodac XAR-5film.
Results
We examined the effect of MGS on the sensitivity of KB/S cells and their P-glycoprotein-overexpressing variant (VJ-300) to vinblastine (VBL). As shown in Fig. 1A and Table  1 , VBL induced cell death with an IC 50 of 2.0 ng/ml in KB/S cells and of 216 ng/ml in VJ-300 cells. MGS did not show significant cytotoxicity up to 50 m g/ml, however, it enhanced the sensitivity to VBL in VJ-300 cells in a dosedependent manner. Furthermore, MGS at 30 m g/ml enhanced the sensitivity to other anti-cancer drugs, such as vincristine (VCR) and taxol (TXL), in VJ-300 cells (Table  1) . P-glycoprotein was also overexpressed in VCR-resistant mouse leukemia P388/VCR cells, and the sensitivity of P388/VCR to VBL was 21-fold lower than that of parental P388/S cells. However, the resistance to VBL in P388/VCR cells was also reduced by the addition of MGS in a dosedependent manner (Fig. 1B) . These results indicated that MGS might be of potential use for the circumvention of MDR. Since the intracellular concentration of anticancer drugs is decreased in P-glycoprotein-overexpressing tumor cells, the intracellular concentration of anticancer drugs in KB/S and VJ-300 cells was measured in the presence or absence of MGS. As shown in (Fig. 2) . These results indicated that the potentiation of the cytotoxicity of anticancer drugs by MGS in P-glycoproteinoverexpressing cells was due to an enhancement of the intracellular concentration of the drugs by MGS.
It was reported that P-glycoprotein is photolabeled with azidopine, and this labeling is inhibited in the presence of compounds that are substrates of P-glycoprotein [12, 13] . Thus, we examined whether MGS inhibited the photolabeling of P-glycoprotein with [ 3 H]azidopine. As shown in Fig. 3 , MGS inhibited the binding of [ 3 H]azidopine to Pglycoprotein in VJ-300 cells in a dose-dependent manner. Hence, the reversing effect of MGS on MDR tumor cells is due, at least in part, to its direct interaction with Pglycoprotein.
Discussion
In the present study, we demonstrated that MGS overcame the resistance to anticancer drugs in P-glycoprotein- overexpressing tumor cells. Several studies have suggested that direct interaction with cytotoxic drug-binding sites on P-glycoprotein was involved in the mechanism of reversing MDR with chemosensitizers. MGS inhibited the binding of [ 3 H]azidopine to P-glycoprotein, therefore, MGS would directly inhibit the function of P-glycoprotein. There are several sites on P-glycoprotein for drug-binding and transport that interact in a cooperative manner [14] . R site preferentially recognizes rhodamine-123, doxorubicin, and daunorubicin. H site preferentially recognizes Hoechst 33342 and colchicine. VBL, actinomycin D, and etoposide interact equally with both sites [14] . Inhibition of the photolabeling by VBL suggests that azidopine interacts with P-glycoprotein at the same site as VBL [15] . Our finding that MGS inhibited the photolabeling with azidopine indicates MGS directly interacts at the azidopineand VBL-binding site of P-glycoprotein. Because MGS is an effective inhibitor of P-glycoprotein, the results of more advanced in vivo tests will be pivotal in contemplating further development of MGS as a clinically useful pharmaceutical agent.
